/Nexus - 1406 - New Times Magazine/pages/0080/image.png)
Page Content (OCR)
ose Vitamin B12 in Treating Alzheim Continued from page 28 Allowance (RDA). For B12, the adult — trivial cost? Just think about that, and the RDA dasage is onlv 3 07 microorams answer hecames ahvions 0 trivial cost? Just think about that, and the answer becomes obvious. oo Allowance (RDA). For B12, the adult RDA dosage is only 3.02 micrograms. Millions will suffer and die from this terrible B12-preventable disease if that Codex regulation is enforced. And a new bill in Congress, cited in TLf{DP (November 2005) by David Musnick, MD, will reinforce Codex restrictions. One final note. It is important to cultivate a positive, optimistic outlook to maximise the prospect for success against such mental diseases. One should avoid the scenario in which the attending physician tells the cancer patient, "You have x months to live". Classes and groups for Alzheimer's-fearing people often move in that direction. In fact, I have heard of no AD awareness classes that even mention vitamin B12 therapy in a positive way. Physicians, whose medical education omitted or put a negative spin on anything using nutrition, may be behind the structure of many such classes. What a different story it might be if instruction and awareness emphasised the usually successful measures brought out in this article. One has to ask: why don't doctors at least tell the public about this seemingly magical therapy, which is available to all at In that vein, I offer a caution on cholesterol-lowering statin drugs. Ten years ago I exposed these high-margin products, along with others, as potential patient- killers.'"° Big Pharma is waking up belatedly to that fact. Now pharmaceutical companies would like to promote statins as preventives for Alzheimer's dementia. Drug therapies reported up to September 2005 showed no success (Acres USA, September 2005). A recent CBS Evening News report quoted a University of California medical professor who is conducting new government-funded (not drug-maker- funded) research on statin drugs' effect on Alzheimer's-susceptible patients: "We have people who have lost thinking ability so rapidly that within the course of a couple of months they went from being heads of major divisions of companies to not being able to balance a checkbook and being fired from their companies.""""'"* Vitamin B12 therapy still faces a very real obstacle: Codex regulations, likely to go into effect in the near future, will prohibit any dose of any vitamin to be sold at much above the Recommended Dietary Editor's Note: Due to the length of the endnotes accompanying this article, we are unable to publish them here; however, they can be accessed via our website, http://www.nexusmagazine.com. About the Author: Joseph G. Hattersley has an MA in Economics from the University of California-Berkeley. In 1953, he completed all requirements for a PhD except the dissertation. In 1976, at age 54, a seeming nutritional miracle launched his career of writing on a wide range of health topics. Mr Hattersley has previously contributed two articles to NEXUS: "Soybean Products: A Recipe for Disaster", in vol. 4, no. 3, and "The Healing Power of Full-spectrum Light" in vol. 8, no. 4. Mr Hattersley can be contacted by post at 2209 Craig Road SE, Olympia, WA 98501, USA, by telephone on +1 (360) 352 3688 and by email on jghattersley@yahoo.com. NEXUS * 79 OCTOBER — NOVEMBER 2007 www.nexusmagazine.com